Galapagos Toekomstige groei

Future criteriumcontroles 0/6

De winst van Galapagos zal naar verwachting dalen met 24.2% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 3.9% per jaar. De winst per aandeel zal naar verwachting dalen met 19.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -5.6% zijn.

Belangrijke informatie

-24.2%

Groei van de winst

-19.1%

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	3.9%
Toekomstig rendement op eigen vermogen	-5.6%
Dekking van analisten	Good
Laatst bijgewerkt	07 Nov 2024

Recente toekomstige groei-updates

Recent updates

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Oct 03

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Jul 25

Galapagos: Can The Company Turn Around?

May 19

Galapagos: A History Of Disruptive Failures

Feb 22

Galapagos: The Investment Thesis Is More Appealing Than Ever

Dec 02

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Jun 04

Galapagos reports Q1 results

May 06

Galapagos: Market Values Pipeline Below $0

Dec 30

Galapagos candidate shows positive action in IPF proof-of-concept study

Nov 30

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Galapagos Is A Buy Despite Setback In The U.S.

Oct 23

Winst- en omzetgroeiprognoses

NasdaqGS:GLPG - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	313	-86	-495	-350	10
12/31/2025	299	-80	-497	-352	11
12/31/2024	289	-36	-285	-335	10
9/30/2024	260	-61	-412	-328	N/A
6/30/2024	261	32	-458	-375	N/A
3/31/2024	244	31	-455	-434	N/A
12/31/2023	240	-4	-425	-406	N/A
9/30/2023	544	-153	-538	-519	N/A
6/30/2023	86	-46	-545	-517	N/A
3/31/2023	163	-69	-565	-533	N/A
12/31/2022	241	-71	-537	-501	N/A
9/30/2022	577	6	-536	-484	N/A
6/30/2022	505	-81	-560	-504	N/A
3/31/2022	507	-126	-503	-445	N/A
12/31/2021	234	-121	-562	-504	N/A
9/30/2021	474	-201	-459	-377	N/A
6/30/2021	537	-219	-507	-421	N/A
3/31/2021	488	-272	-567	-480	N/A
12/31/2020	478	-311	-519	-427	N/A
9/30/2020	455	-368	-579	-510	N/A
6/30/2020	972	75	3,079	3,141	N/A
3/31/2020	948	145	3,156	3,211	N/A
12/31/2019	835	149	3,163	3,209	N/A
9/30/2019	865	280	3,250	3,281	N/A
6/30/2019	324	-66	-211	-193	N/A
3/31/2019	314	-41	-190	-174	N/A
12/31/2018	318	-29	-156	-142	N/A
9/30/2018	255	-74	-166	-156	N/A
6/30/2018	185	-126	N/A	-187	N/A
3/31/2018	161	-139	N/A	-164	N/A
12/31/2017	156	-116	N/A	-147	N/A
9/30/2017	193	-40	N/A	-51	N/A
6/30/2017	176	-27	N/A	-42	N/A
3/31/2017	177	4	N/A	-35	N/A
12/31/2016	152	54	N/A	239	N/A
9/30/2016	78	-49	N/A	180	N/A
6/30/2016	72	-52	N/A	178	N/A
3/31/2016	55	-68	N/A	170	N/A
12/31/2015	61	-118	N/A	-115	N/A
9/30/2015	75	-72	N/A	-108	N/A
6/30/2015	82	-57	N/A	-96	N/A
3/31/2015	88	-44	N/A	-87	N/A
12/31/2014	90	-37	N/A	-76	N/A
9/30/2014	86	-32	N/A	-53	N/A
6/30/2014	92	-25	N/A	-32	N/A
3/31/2014	94	-21	N/A	-15	N/A
12/31/2013	97	-17	N/A	2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat GLPG de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat GLPG de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat GLPG de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van GLPG ( 3.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van GLPG ( 3.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat GLPG binnen 3 jaar verliesgevend zal zijn.

Galapagos Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Recent updates

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Galapagos NV Announces Board Changes

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

Galapagos NV Announces Board Changes

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

Galapagos: Can The Company Turn Around?

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Galapagos: A History Of Disruptive Failures

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos: The Investment Thesis Is More Appealing Than Ever

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos reports Q1 results

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Galapagos: Market Values Pipeline Below $0

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial

Galapagos NV Announces First Dosing in MANGROVE Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos candidate shows positive action in IPF proof-of-concept study

Selvita S.A. (WSE:SLV) signed an agreement to acquire 100% stake in Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG) for an enterprise value of €31.2 million.

Galapagos NV Announces Dosing of the First Psoriasis Patient in the Phase 1B Trial with GLPG3667

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Gilead Sciences, Inc. and Galapagos NV Announce the Application for A New Indication to the Approved License

Galapagos NV Unveils the Toledo Target Family as a Series of Salt-Inducible Kinase Inhibitors

Galapagos Is A Buy Despite Setback In The U.S.

Galapagos and Servier Report Topline Results for Roccella Phase 2 Clinical Trial with Glpg1972/S201086 in Knee Osteoarthritis Patients

Phase 2B/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel